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Abstract
Osteoblasts and endothelium constitute functional niches that support hematopoietic stem cells
(HSC) in mammalian bone marrow (BM) 1,2,3 . Adult BM also contains adipocytes, whose
numbers correlate inversely with the hematopoietic activity of the marrow. Fatty infiltration of
hematopoietic red marrow follows irradiation or chemotherapy and is a diagnostic feature in
biopsies from patients with marrow aplasia 4. To explore whether adipocytes influence
hematopoiesis or simply fill marrow space, we compared the hematopoietic activity of distinct
regions of the mouse skeleton that differ in adiposity. By flow cytometry, colony forming activity,
and competitive repopulation assay, HSCs and short-term progenitors are reduced in frequency in
the adipocyte-rich vertebrae of the mouse tail relative to the adipocyte-free vertebrae of the thorax.
In lipoatrophic A-ZIP/F1 “fatless” mice, which are genetically incapable of forming adipocytes8,
and in mice treated with the PPARγ inhibitor Bisphenol-A-DiGlycidyl-Ether (BADGE), which
inhibits adipogenesis9, post-irradiation marrow engraftment is accelerated relative to wild type or
untreated mice. These data implicate adipocytes as predominantly negative regulators of the bone
marrow microenvironment, and suggest that antagonizingmarrow adipogenesis may enhance
hematopoietic recovery in clinical bone marrow transplantation.
At birth, hematopoietic red marrow occupies virtually the entirety of the bone marrow space,
but with age, non-hematopoietic fatty marrow gradually predominates 4. This so-called
“fatty degeneration” of the marrow is a dynamic and reversible process 5,6. To investigate
whether marrow adipocytes influence hematopoiesis, we surveyed the mouse skeleton for
bones that harbour fatty marrow under normal conditions. We found that the spine of adult
mice manifests a proximal to distal gradient of bone marrow adipocytes: thoracic vertebrae
are virtually adipocyte-free, while vertebrae starting at the level of the third or fourth tail
segments are highly adipocytic (figure 1a). We isolated bone marrow from the thoracic and
tail vertebrae of 12 week-old mice and quantified the hematopoetic stem cell and short-term
progenitor compartments both phenotypically and functionally (schema in supplementary
3Corresponding author: George Q. Daley, Division of Hematology/Oncology, Children’s Hospital Boston, 300 Longwood Avenue –
Karp 7th, Boston, MA 02115, Phone: 617 970 0216 / Fax: 617 730 0222, Email: george.daley@childrens.harvard.edu.
*These authors have contributed equally to this work
Author Contributions: O.N and G.Q.D. conceived the original idea, designed experiments and wrote the manuscript. O.N., V.N. and
P.W. performed experiments and analyzed results. O.N. and F.F. performed quantitative acquisition and analysis of mCT and mPET.
All authors edited and reviewed the final manuscript.
Author Information: Reprints and permissions information is available at npg.nature.com/reprintsandpermissions.
NIH Public Access
Author Manuscript
Nature. Author manuscript; available in PMC 2010 March 3.
Published in final edited form as:
Nature. 2009 July 9; 460(7252): 259–263. doi:10.1038/nature08099.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
figure 1). BM from tail vertebrae contains only 25% as many CD45+ hematopoietic cells per
segment as thoracic BM, thus confirming the reduced overall hematopoietic cellularity
evident by histology (figure 1b, supplementary figure 2a). Using flow cytometry, we
determined the relative frequency of hematopoietic stem cells (HSC, ckit+Sca1+Lin-Flk2-
or KLSF), multipotent progenitors (MPP), common myeloid progenitors (CMP),
granulocyte-monocyte progenitors (GMP), and megakaryocyte-erythroid progenitors (MEP)
in these different regions of the spine 10. The percentage of all progenitor classes was
reduced 2–3 fold in the CD45+ hematopoietic cells of adipocyte-rich BM of the tail
vertebrae compared to non-adipocytic BM from the thoracic vertebrae (figure 1c,
supplementary figure 2b). Congruent with the FACS phenotype data, long-term repopulating
HSCs, short-term repopulating progenitors, spleen colonies and methylcellulose colony
forming units were reduced 1.5–3 fold in adipocyte-rich BM from tail vertebrae as
compared to adipocyte-free BM from the thoracic vertebrae (figure 1d–1f, supplementary
figure 2c). These phenomena are neither due to age nor weight-bearing status, for we
observed a similar reduction in the frequency of short-term progenitors in younger (4 week-
old) and older mice (13 months), as well as in another consistently fatty yet weight-bearing
region of the mouse skeleton, the distal tibia (supplementary figures 3a–3f). Reduced
frequency of CMPs and primitive CFUs also accompany the increased BM adiposity of
femurs from leptin deficient obese mice (supplementary figure 4a–4d). Moreover, we found
that BM-derived adipocytes reduce the expansion of hematopoietic cells in stromal transwell
co-cultures, indicating that adipocytes release diffusible inhibitors of hematopoiesis
(supplementary figure 5a–5d). We therefore conclude that adipocyte-rich marrow is
associated with lower absolute levels and relative numbers of hematopoietic progenitors.
To investigate the mechanism of reduced hematopoietic activity of adipocytic BM, we
performed cell cycle analysis of the progenitor compartments. In all cases, we found fewer
progenitors in the replicating phases of the cell cycle (S/G2/M) within the adipocyte-rich
BM (figure 1g, supplementary figure 6a). Early progenitors (HSC/MPP) presented no
significant difference in their G0/G1 ratio, while late progenitors (GMP/CMP/MEP)
presented a significant increase in the G0/G1 ratio (supplementary figure 6b). To determine
if the slow-cycling HSCs within the tail BM were functional, as opposed to senescent, we
FACS-sorted HSCs (ckit+Lin-Sca1+Flk2-, KLSF) and transplanted them competitively into
lethally irradiated mice. We observed no difference in repopulating activity between HSCs
from tail and thorax in the first month post-transplant. However, multilineage long-term
engraftment was significantly higher in HSCs purified from tail BM (figure 1h), suggesting
that the slow-cycling progenitors in adipocytic tail BM are relatively quiescent and not
senescent. This is consistent with the relative predominance of CD34low HSCs within the
KLSF fraction of tail BM (figure 1i), a phenotype associated with long–term repopulation
activity 11. Taken together, our data establish tail vertebrae as a model for the study of fatty
marrow in the mouse, and demonstrate that adipocyte-rich marrow manifests altered
hematopoiesis. HSCs and short-term progenitors are functionally reduced on a per cell basis
in fatty marrow due to reduced cycling at the level of the HSC, MPP and CMP
compartments.
To determine if the association between adipocytic marrow and reduced hematopoietic
progenitor frequency is purely correlative, or whether adipocytes actively compromise
hematopoiesis, we studied the lipoatrophic “fatless” A-ZIP/F1 mouse, which cannot form
adipocytes due to the expression of a dominant negative form of C/EBP under the adipocyte
fatty-acid binding protein 4 (aP2/FABP4) promoter 8. In contrast to wildtype mice, we
found that the absence of adipocytes in fatless A-ZIP/F1 mice rescued hematopoiesis in the
tail, such that A-ZIP/F1 mice presented no significant difference in the frequency of CFUs
from thorax or tail BM (supplementary figure 7a–b), indicating that compromised
osteogenesis due to the non-weight-bearing nature of these bones cannot explain the
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hematopoietic defect of wildtype, adipocyte-rich tail vertebrae 12. Importantly, although
fatless A-ZIP/F1 mice are diabetic, their blood counts were similar to controls during
homeostasis, and their femoral BM showed no competitive advantage over BM from wild-
type littermates, arguing that the diabetic milieu does not account for the observed
alterations in the hematopoietic compartment (supplementary figures 8a–c). We therefore
conclude that the presence of adipocytes is necessary to observe reduced hematopoiesis in
adipocyte-rich tail bone marrow.
We then analyzed the effect of adipocytes on hematopoietic recovery following bone
marrow transplantation. Between the second and fourth week after lethal irradiation, the
bone marrow space throughout the mouse skeleton becomes replaced by adipocytes. During
this post-transplant period mice (and human patients) depend on fast cycling, short-term
hematopoietic progenitors to rescue their otherwise lethal pancytopenia 13. Given our prior
data, we predicted that the compromised adipogenesis in the A-ZIP/F1 mouse would
enhance hematopoietic recovery in the post-transplant period through increased proliferation
of short-term progenitors. We transplanted wildtype BM (CD45.2) into either wildtype or
fatless A-ZIP/F1 littermates (CD45.1, figure 2a). In contrast to control mice, A-ZIP/F1
fatless mice exposed to lethal doses of irradiation produced markedly fewer adipocytes in
the marrow cavity (figure 2b). We monitored leukocyte recovery in the post-transplant
period and found that recovering A-ZIP/F1 fatless mice have up to 4 times higher leukocyte
counts in peripheral blood relative to their wild-type controls (figure 2c). We also observed
significantly accelerated recovery in the hemoglobin content of peripheral blood (figure 2d).
Importantly, both wildtype and A-ZIP/F1 fatless recipients showed comparable high-level
long-term donor chimerism after the primary transplant (supplementary figure 8d). In the
third week post-transplant, we recovered the donor CD45.2 BM from the adipocyte-rich
wildtype or the adipocyte-free AZIP/F1 femurs. We found a pronounced increase in
hematopoietic progenitors in the recovering CD45.2 BM isolated from fatless A-ZIP/F1
mice as determined by flow cytometry (figure 2e), methylcellulose colony forming assays
(figure 2f and supplementary figure 8e) and short-term competitive repopulation into
secondary recipients (figure 2g). Collectively, these results indicate that the lack of
adipogenesis in A-ZIP/F1 recipient mice enhances hematopoietic recovery after lethal
irradiation by enhancing engraftment of short-term progenitors, and further supports the
conclusion that adipocytes in fatty marrow hinder hematopoietic progenitor expansion.
During our studies, we observed that bone marrow ablation in lethally irradiated A-ZIP/F1
fatless mice was accompanied by marked osteogenesis. Trabecular bone was increased in
the femurs of transplanted A-ZIP/F1 fatless mice compared to wild-type controls (figure 3a),
a phenomenon also apparent in the tail and in mice that were lethally ablated but received no
transplant (supplementary figures 9a–c). High-resolution micro-Computerized Tomography
(mCT) confirmed a 5-fold increase in trabecular bone that was specific to fatless A-ZIP/F1
mice after BM transplantation (figure 3a–c). Incorporation of 18F measured by positron
emission tomography (mPET) confirmed an increased bone metabolism, indicating new
bone deposition in tails and tibias after bone marrow transplantation that was maximal in the
second week post-transplant (figure 3d–e). Our data show that simultaneous ablation of the
hematopoietic and BM adipocyte compartment can induce osteogenesis, which, as shown by
others, promotes a more supportive environment for hematopoietic reconstitution that could
explain the positive effect of adipocyte ablation in BM engraftment 1, 2. Our observation is
compatible with a previous report that surgical removal of the fatty marrow in rabbit tibias
induces transient hematopoietic infiltration and new osteoid and trabecular bone formation
14. In addition to creating an osteogenic environment, fatless A-ZIP/F1 mice may
accumulate mesenchymal elements that support hematopoietic recovery, or may be deficient
in osteoclast elements that would antagonize trabecular bone growth during the recovery
phase of lethal irradiation. Importantly, preventing the formation of BM adipocytes alone
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does not cause osteogenesis 15, indicating that osteogenesis requires simultaneous ablation
of both the adipocytic and hematopoietic compartments. These data suggest a three-way co-
regulation of hematopoiesis, osteogenesis and adipogenesis within the BM compartment.
Finally, we tested whether blocking adipogenesis pharmacologically could enhance bone
marrow engraftment in wild-type mice. The PPARγ inhibitor Bisphenol-A-DiGlycidyl-
Ether (BADGE) has been shown to prevent bone marrow adipocyte formation in vitro and in
vivo in models of streptozotocin-induced diabetes 9, 15 . Importantly, BADGE does not
enhance hematopoietic colony formation in vitro, when BM cells are isolated from their
stromal microenvironment (supplementary figure 10). We administered BADGE to lethally
irradiated mice for the two weeks following bone marrow transplantation, and observed
successful inhibition of BM adipocyte formation (figure 4a), higher peripheral blood
leukocyte counts (figure 4b), and an enrichment in colony forming units (figure 4c). Our
results demonstrate that the negative influence of adipocytes on post-transplant
hematopoietic engraftment can be overcome pharmacologically, and suggest that PPARγ
inhibitors, or other adipocyte inhibitors such as the novel aP2 inhibitor BMS309403 16,
might serve as adjuvants to hematopoietic recovery in clinical bone marrow transplantation.
Collectively, our results contradict the classical dogma that adipocytes act as passive space
fillers in the marrow. We demonstrate that adipocyte-rich marrow harbors a decreased
frequency of progenitors and relatively quiescent stem cells. Moreover, we observe that
mice that are genetically deficient in adipogenesis show accelerated hematopoietic recovery
after bone marrow ablation, a phenomenon that can be reproduced pharmacologically in
wild-type mice through PPARγ inhibition. These results suggest a novel therapeutic
approach to enhance hematopoietic engraftment following marrow or cord blood
transplantation, or to ameliorate aplasia in genetic bone marrow failure syndromes.
Furthermore, our results suggest a plausible mechanism for the reports of
myelosuppression17, 18, 19 in patients treated with the PPARγ agonist rosiglitazone, a
diabetes drug known to increase marrow adiposity 20.
Our data indicate a predominantly suppressive influence of adipocytes on hematopoiesis
within the bone marrow microenvironment. BM adipocytes are less supportive of
hematopoiesis in vitro than their undifferentiated stromal or pre-adipocytic counterparts, in
part due to reduced production of growth factors such as GM-CSF and G-CSF 21, 22 .
Moreover, adipose tissue secretes neuropillin-1 23, lipocalin 2 24, 25, adiponectin 26 and
TNFalpha 27, 28 , each of which can impair hematopoietic proliferation. Of note, TNFalpha
and adiponectin inhibit progenitor activity while positively influencing the most primitive
HSCs 27, 29, suggesting that adipocytes prevent hematopoietic progenitor expansion while
preserving the hematopoietic stem cell pool. Adipocytes and osteoblasts originate from
mesenchymal stem cells within the bone marrow, where both compartments hold a
reciprocal relationship 30. Balancing the supportive role of the osteoblast in the HSC niche,
our data implicate adipocytes as negative regulators of hematopoiesis. Further studies will
address the molecular players involved in the hematopoietic inhibition imposed by fatty
marrow.
Methods Summary
Thorax, tibias and tails were isolated from wildtype C57BL6/J mice. B6.SJL-Ptprca Pep3b/
BoyJ were used as bone marrow donors to exploit the CD45.1/CD45.2 allelic system
(Jackson Laboratoriess #0002014). Bone marrow transplantation and CFU-Spleen assays
were performed on lethally irradiated mice (two 5.5Gy doses separated by 3hrs) and cells
were administered by tail vein injection within 24hrs of lethal irradiation. For competitive
transplantation, samples were competed against 250,000 recipient-matched competitor
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femoral bone marrow. FVB wildtype litter-mates mice were used as controls for FVB.A-
ZIP/F1 fatless mice. During BM transplantation assays FVB or FVB.A-ZIP/F1 mice
(CD45.1) received 200,000 MHC-matched (Hq) wildtype BM from DBA/1J mice (CD45.2).
Secondary transplants were performed through recovery of the CD45.2 DBA/2 BM passed
through the FVB wildtype or FVB.A-ZIP/F1 microenvironment, which was then
transplanted into FVB (CD45.1) recipients together with 250,000 FVB (CD45.1) wildtype
competitor BM cells. For pharmacological inhibition of adipocyte formation, BM
transplants were performed in wild-type female FVB mice as described above, except that
30mg/kg BADGE or control vehicle (DMSO 10%) were administered in daily
intraperitoneal injections starting one day prior to irradiation and continuing until day 14
post-transplant. 500mg BADGE (Fluka) was resuspended in 8.3ml DMSO (Sigma) and
diluted in PBS to a final concentration of 10% DMSO for administration at 30mg/kg in
100ul. Aliquots were stored at −20°C and thawed daily. Multicolor flow cytometry was
performed in a BD five-laser LSRII flow cytometer. Cell cycle analysis was performed with
DAPI (Sigma) in cells fixed in 2% paraformaldehyde for 15 min at 4°C. For all statistical
analysis un-paired two-tailed Student’s t-test was performed assuming equal variance of
samples. Error bars and confidence intervals represent the standard error of the mean (SEM)
unless otherwise indicated.
Methods
Animals
All mice were purchased from Jackson Laboratories and sex, weight and age-matched or
breeding colonies were established in house. Experiments were carried out with IACUC
approval from CHB.
Bone marrow preparations
Femurs, thorax and tails were isolated free of muscle and tendons; when appropriate, the
spinal cord was carefully removed. Bones were crushed in IMDM with mortal and pestle,
filtered through a 70-µm filter and washed with PBS. A sample was removed, stained with
CD45-FITC (1:200) and 7-AAD (1:100) in 50 ul and the volume raised to 500ul with PBS
and reference beads (Sigma). A viable CD45+ cell count was then obtained with a F500-
Coulter flow cytometer. Red blood cells from bone marrow in homeostatic conditions (pre-
transplant) were lysed with RBC lysis buffer (Sigma). For early post-transplant analysis,
BM was not lysed and efforts were made to perform minimal manipulation before CFU
plating or secondary transplantation (RBCs were excluded as counts were based on CD45+
cells only).
Flow cytometry
Multicolor analysis for progenitor and stem cell quantification was performed on a FACS-
Aria+UV or on a 5-laser-LSRII flow cytometer (BD). Cells were stained in PBS 2% FCS for
1 hour with CD34-FITC (1:50, BD), Flk2-PE (1:100, BD), Lineage cocktail-PECy5
(Ter119/B220/CD19/CD3/CD4/CD8/Nk1.1 from eBiosciences; mixed 1:1 except CD3 2:1,
and used 1:200), FcγRIII/II-PECy7 (1:200, Biolegend), ckit-APC (1:200, BD), CD45.1 or
CD45.2-APCCy7 (1:100, Biolegend), CD45-biotin (1:200, BD), Streptavidin-Pacific
Orange (1:2000, Invitrogen), and Sca1-Pacific Blue (1:100 Biolegend). For cell cycle
analysis, bone marrow cells were stained in cold 2%IFS and fixed in cold 2% PFA for 15
minutes, then washed, stained in DAPI solution for 10 minutes at room temperature (0.1%
(v/v) Triton X-100 and 1 µg/ml DAPI in PBS 41,42), washed and immediately analyzed.
Ki-67 analysis was done as described by Wilson et al.31. Bone marrow cells were stained by
cell surface markers (Sca1-FITC (1:100, BD), Lineage-cocktail (1:200), FcγRIII/II-PECy7
(1:200, Abcam), ckit-APC (1:200), CD45-APCCy7 (1:100, BD), CD150-biotin (1:300,
Naveiras et al. Page 5
Nature. Author manuscript; available in PMC 2010 March 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
BioLegend), Streptavidin-Alexa Fluor 680 (1:200, Invitrogen)), washed, fixed in cold
Cytofix/Cytoperm buffer (BD) for 20 minutes, then washed and incubated in Permwash
buffer (BD) with Ki-67-PE (1:100, BD) for 5 hours at 4°C. Cells were treated with 1 µg/ml
DAPI for 10 minutes, washed and resuspended in PBS 2% FCS immediately prior to
acquisition.
Progenitor assays
Colony forming unit (CFU) assays were performed in complete M3434 methylcellulose
(Stem Cell Technologies) following the manufacturer’s instructions. Colonies were scored
on day 8–10 on coded plates for unbiased counts.
Bone marrow transplantation
Mice were lethally irradiated with 11-12Gy split-dose 2.5hrs apart, and BM transplants
performed within 24h by tail-vein injection. Engraftment was measured monthly through
eye bleed and FACS analysis with CD45.1-FITC (eBiosciences), CD45.2-PE or CD45.2-
biotin, CD3-PE, CD19-PE, Mac-1-PE. Gr1-PE, F4/80-APC. All antibodies were ordered
from Beckton-Dickinson unless otherwise specified. Mice whose engraftment was below
0.5% were considered non-engrafted and were not taken into account for calculation of
competitive repopulation units.
Stromal cell culture and differentiation
OP9 cells (ATCC) were expanded in MEMalpha 15%IFS + pen/strep/glutamine (Gibco);
media changed every 3–4 days. Adipocytic differentiation was performed on confluent OP9s
plated at 10,000/cm2 with isobutylmethylxantine 0.5mM (IBMX, Sigma 1000x stock in
DMSO), insulin 5ug/ml (Sigma, 1000x stock in PBS) and dexamethasone 10e-6M (Sigma,
1000x stock in ethanol) on the first week, then maintained with insulin and dexamethasone
only for another 10 days Media changes were made every 3–4 days with fresh aliquots
maintained in the dark at −20°C. Hematopoietic co-cultures with FACS-sorted ckit+Lin-
Sca1+ (KLS) hematopoietic stem cells were performed in IMDM 10% IFS at 37°C and
5%CO2; media was changed on the seventh day of co-culture. For co-cultures, 2000 KLS
cells were plated per well. Transwell assays used 12mm polyester inserts with 0.4µm pore
size (Corning) with adipocytic or undifferentiated OP9 cells plated in the bottom of the plate
while undifferentiated OP9s were co-cultured with KLS in the upper insert.
MicroPET analysis
For micro Positron Emission Tomography (mPET), mice were administered equal doses
(5.6–9.3 MBq) of sodium fluoride-18 (F-18) by tail-vein injection. Animals were imaged
prior to bone marrow transplantation, and the same cohort of animals was re-assayed at
different times post-transplant. Exactly 30min after the F-18 injection, mice were imaged
with a Focus 120 microPET scanner (Siemens). For normalization, the total dose injected
was determined immediately pre- and post-imaging by introducing the anesthesized mouse
in the dose calibrator and calculating the mid-acquisition dose as the average of the pre- and
post-acquisition measurements adjusted by time decay. ASIPro software (Siemens) was then
used for image analysis. To determine the F-18 uptake in tibias and tails, a 3D ROI (region
of interest) was created in transverse sections through the selection of six 9×9 pixel planes
moving distally from the tibial plate or 12 planes moving distally from the beginning of the
free tail. The mean dose in the ROI (Bq/ml) was then normalized to the total injected dose
and the ratios from pre to post-transplant F18-uptake were then calculated. When the whole
cohort of mice could not be assayed on the same day post-transplant, data from the two
closest dates was interpolated.
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MicroCT analysis
For high-resolution micro Computerized Tomography (mCT) analysis, tibias were dissected,
fixed in 10% formalin, and imaged with the Siemens microCAT II system.using a 22.75
micrometer pixel size. Beam angle of increment was 1 degree and tube voltage and current
were 80 kvp and 450 μA per view as described by Botolin et al. 44. Each run included
wildtype and fatless bones and a calibration phantom to calibrate grayscale values with
respect to mass density and maintain consistency. A fixed density threshold was established
through normalization to the phantom to separate trabecular bone from bone marrow (1350
mg/ml). Trabecular bone analyses were done with ImageJ and AMIRA image analysis
software in a 0.2mm thick 3D square region of trabecular bone defined at 1 mm under the
growth plate of the proximal tibia extending 0.9 mm toward the diaphysis and excluding the
outer cortical shell.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hematopoietic stem cells and progenitors are reduced in number, frequency and
cycling capacity in adipocyte-rich bone marrow during homeostasis
a.H&E-stain of decalcified thoracic vertebra (top) and fourth-tail-segment (bottom), 12-
week-old C57BL/6J mice. b.Absolute number of hematopoietic cells (CD45+) per vertebral
segment. c.Progenitor frequency within the hematopoietic compartment (CD45+).
d.Competitive engraftment (250,000 CD45.1 tail or thorax BM; 250,000 CD45.2 competitor
BM), e.Day 13 spleen-colony assay, and f.CFU-progenitor assay from tail and thorax BM.
g.Progenitor cell cycle analysis .average % cells in S/G2/M transition ± SEM. h.100 tail and
thorax BM sorted HSC (ckit+Lin-Sca1+Flk2−; >95% purity) were transplanted
competitively, then engraftment in peripheral blood monitored. i.CD34 expression within
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the HSC fraction (KLSF, ckit+Lin-Sca1+Flk2−); % CD34low within KLSF fraction
indicated.
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Figure 2. The lack of bone marrow adipocytes post-irradiation in fatless mice enhances
hematopoietic progenitor expansion and post-transplant recovery
a.Experimental design. Wildtype FVB or fatless FVB.A-ZIP/F 16-week-old mice (CD45.1)
were lethally irradiated and transplanted with 200,000 CD45.2, MHC-compatible DBA/1
wild-type BM. Femurs were isolated on day 17–20 post-transplant and donor DBA CD45.2
wildtype BM was recovered by high purity FACS, then used for progenitor assays or
competitive serial transplantation. b.Femoral H&E in the third week post-transplant. c.White
blood cell (WBC) counts and d.hemoglobin levels in peripheral blood after primary
transplant. BM recovered from primary transplants was assayed for e.relative frequency of
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progenitors by FACS (± STD) f.colony forming units assay (CFU), and g.secondary
competitive transplantation into wildtype recipients.
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Figure 3. Ablation of the hematopoietic compartment in fatless A-ZIP/F1 mice during BM
transplantation induces osteogenesis
Analysis of mice transplanted as in figure 2. a.High-resolution microCT analysis of pre/
post-transplant tibias from wildtype (top) or fatless A-ZIP/F1 mice 20 days after lethal
ablation. b.Average trabecular bone density of (a) normalized to a density standard
(phantom). c.Percentage BM space occupied by trabecular bone 20 days after
transplantation. d.MicroPET analysis pre/post-transplant. Representative mice shown at
three different timepoints (3–4 analyzed per group). Dark areas indicate NaF-18 uptake in
regions of active bone deposition (red arrowheads). e.Quantification of mean NaF-18 uptake
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in tibiae and proximal tails pre/post-transplantation. Square and lines over micrographs a.
and d. indicate quantification regions (see methods).
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Figure 4. Pharmacological inhibition of adipocyte formation enhances BM engraftment in wild-
type mice
BM transplants were performed in wild-type female FVB mice as described for figure 2
except that 30mg/kg BADGE or control vehicle (DMSO 10%) were administered through
daily intra-peritoneal injections from the day prior to irradiation until day 14 post-transplant.
a.H&E stain of femurs from mice sacrificed on day 17 post-transplant, when the donor
CD45.2 wildtype BM was recovered and purified by FACS. b.White blood cell (WBC)
counts in peripheral blood on the post-transplant period show accelerated recovery in
BADGE-treated mice. c.Colony forming unit assay (CFU) from the recovered donor BM
Naveiras et al. Page 16
Nature. Author manuscript; available in PMC 2010 March 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
